NBIX vs PD · P/E 45, rev $2.36B vs P/E 4.2, rev $467.5M
Neurocrine Biosciences Inc (NBIX) versus Pagerduty Inc (PD) — a side-by-side from cached financials, not a winner call.
Neurocrine Biosciences Inc (NBIX) is a drug manufacturers - specialty & generic company listed on US.
Pagerduty Inc (PD) is a software - application company listed on NYSE.
Latest reported NBIX revenue for 2024-12-31 was $2.36B. Net income was $341.3M. Revenue was up 24.8% from 2023-12-31 to 2024-12-31. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
Latest reported PD revenue for 2025-01-31 was $467.5M. Net income was -$43.5M. Revenue was up 8.5% from 2024-01-31 to 2025-01-31. PD currently screens at market cap $664.8M and trailing P/E 4.2.
NBIX currently screens at market cap $13.21B and trailing P/E 45.2. PD currently screens at market cap $664.8M and trailing P/E 4.2.
Not investment advice. Open the NBIX and PD stock pages for the full models.
Not investment advice.